POSTED: March 24, 2014

Zocere to Present at 2014 Life Sciences & Healthcare Venture Summit in New York

Zocere to Present at 2014 Life Sciences & Healthcare Venture Summit in New York   ALBUQUERQUE, N.M., March 26, 2014 – – New Mexico-based pharmaceutical company Zocere, Inc., will be making its case to investors at the 2014 Life Sciences & Healthcare Venture Summit in New York City April 2. (continued…)


POSTED: March 10, 2014

Zocere Licenses Neuroprotectant Technology for Stroke and Other Brain Trauma from STC.UNM

ALBUQUERQUE, N.M., March 10, 2014 – – Zocere, Inc., has signed a licensing agreement for a novel neuroprotectant treatment for ischemic stroke and other neurological disorders from STC.UNM, the University of New Mexico’s technology transfer and economic development organization.   Zocere is a New Mexico-based pharmaceutical company developing drug-based treatments (continued…)


Zocere Appoints Zavitz as Chief Scientific Officer
POSTED: February 10, 2014

Zocere Appoints Zavitz as Chief Scientific Officer

Albuquerque, N.M., February 11, 2014 – – New Mexico-based pharmaceutical company, Zocere, Inc., has named Kenton H. Zavitz, Ph.D. as its chief scientific officer. Zocere is developing an injectable neuroprotectant drug designed to combat brain injury resulting from stroke and other head trauma such as concussion. Zavitz has more than (continued…)


Zocere Featured in BioCentury
POSTED: January 31, 2014

Zocere Featured in BioCentury

Emerging Company Profile Zocere: Stepping up in stroke By Lauren Martz Staff Writer Zocere Inc. may have found a new way to decrease ischemic brain injury in patients following stroke. The company is developing an injectable, degradation-resistant version of the neuroprotective STEP peptide that could improve patient outcomes when given (continued…)


Former Glaxo Pharma Exec Adrian Hobden Joins Zocere Board
POSTED: January 30, 2014

Former Glaxo Pharma Exec Adrian Hobden Joins Zocere Board

Albuquerque, N.M., January 30, 2014 – – New Mexico-based pharmaceutical company, Zocere, Inc., has named former pharmaceutical executive Adrian Hobden, Ph.D., to its Board of Directors. Hobden has been instrumental in developing and commercializing pharmaceuticals for a range of disease areas, including cancer, Alzheimer’s disease, cardiovascular, respiratory, HIV, and antifungals. (continued…)


POSTED: January 15, 2014

Tyrosine Pharma Changes Name to Zocere, Inc.

Albuquerque, N.M., January 16, 2014 – – Tyrosine Pharma, Inc., a New Mexico-based pharmaceutical company, has changed its name to Zocere, Inc. The shift in nomenclature reflects the company’s focus on expanding its portfolio of injectable, neuro-protectant drugs. Commenting on the name change, Zocere President and CEO Wayne Laslie said (continued…)


Zocere, Inc. Names Laslie CEO
POSTED: November 10, 2013

Zocere, Inc. Names Laslie CEO

Stroke Biotech Company Zocere, Inc. Names Laslie President and CEO ALBUQUERQUE, N.M., November 13, 2013 – Zocere, Inc., Inc., is pleased to announce the appointment of Wayne Laslie as president and chief executive officer. Zocere, Inc. is a New Mexico-based biotech company that is developing a treatment for stroke based (continued…)